Effectiveness of a killed whole-cell oral cholera vaccine in Bangladesh: further follow-up of a cluster-randomised trial

Mohammad Ali, Firdausi Qadri, Deok Ryun Kim, Md Taufiqul Islam, Justin Im, Faisal Ahmmed, Ashraful Islam Khan, K Zaman, Florian Marks, Jerome H Kim, John D Clemens, Mohammad Ali, Firdausi Qadri, Deok Ryun Kim, Md Taufiqul Islam, Justin Im, Faisal Ahmmed, Ashraful Islam Khan, K Zaman, Florian Marks, Jerome H Kim, John D Clemens

Abstract

Background: Killed whole-cell oral cholera vaccines (OCVs) are widely used for prevention of cholera in developing countries. However, few studies have evaluated the protection conferred by internationally recommended OCVs for durations beyond 2 years of follow-up.

Methods: In this study, we followed up the participants of a cluster-randomised controlled trial for 2 years after the end of the original trial. Originally, we had randomised 90 geographical clusters in Dhaka slums in Bangladesh in equal numbers (1:1:1) to a two-dose regimen of OCV alone (targeted to people aged 1 year or older), a two-dose regimen of OCV plus a water-sanitation-hygiene (WASH) intervention, or no intervention. There was no masking of group assignment. The WASH intervention conferred little additional protection to OCV and was discontinued at 2 years of follow-up. Surveillance for severe cholera was continued for 4 years. Because of the short duration and effect of the WASH intervention, we combined the two OCV intervention groups. The primary outcomes were OCV overall protection (protection of all members of the intervention clusters) and total protection (protection of individuals who got vaccinated in the intervention clusters) against severe cholera, which we assessed by multivariable survival models appropriate for cluster-randomised trials. This trial is registered on ClinicalTrials.gov, NCT01339845.

Findings: The study was done between April 17, 2011, and Nov 1, 2015. 268 896 participants were present at the time of the first dose, with 188 206 in the intervention group and 80 690 in the control group. OCV coverage of the two groups receiving OCV was 66% (123 659 of 187 214 participants). During 4 years of follow-up, 441 first episodes of severe cholera were detected (243 episodes in the vaccinated groups and as 198 episodes in the unvaccinated group). Overall OCV protection was 36% (95% CI 19 to 49%) and total OCV protection was 46% (95% CI 32 to 58). Cumulative total vaccine protection was notably lower for people vaccinated before the age of 5 years (24%; -30 to 56) than for people vaccinated at age 5 years or older (49%; 35 to 60), although the differences in protection for the two age groups were not significant (p=0·3308). Total vaccine protection dropped notably (p=0·0115) after 3 years in children vaccinated at 1-4 years of age.

Interpretation: These findings provide further evidence of long-term effectiveness of killed whole-cell OCV, and therefore further support for the use of killed whole-cell OCVs to control endemic cholera, but indicate that protection is shorter-lived in children vaccinated before the age of 5 years than in people vaccinated at the age of 5 years or older.

Funding: Bill & Melinda Gates Foundation.

Translation: For the Bengali translation of the abstract see Supplementary Materials section.

Conflict of interest statement

Declaration of interests We declare no competing interests.

Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. Published by Elsevier Ltd.. All rights reserved.

Figures

Figure 1
Figure 1
Trial profile OCV=oral cholera vaccine. WASH=water–sanitation–hygiene. *The date of dose 2 for the two-dose recipients or the median date of dose 2 of the cycle of vaccination for no-dose or one-dose recipients.
Figure 2
Figure 2
Trend of two-dose oral cholera vaccine coverage (%) over 4 years of follow-up post-vaccination* *In the calculation of vaccine coverage, the numerator was all participants who received two-dose vaccines and who were under follow-up at each time point noted on the x-axis. Days in the x-axis begin with the time of the second dose for the intervention clusters.
Figure 3
Figure 3
Kaplan-Meier plot The plot shows the estimates of the cumulative risk of not having cholera with severe dehydration among the entire population at zero time during 4 years of follow-up post-vaccination (overall vaccine efficacy analysis). The p value (p

References

    1. Ali M, Nelson AR, Lopez AL, Sack DA. Updated global burden of cholera in endemic countries. PLoS Negl Trop Dis. 2015;9
    1. Bhattacharya SK, Sur D, Ali M, et al. 5 year efficacy of a bivalent killed whole-cell oral cholera vaccine in Kolkata, India: a cluster-randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2013;13:1050–1056.
    1. Franke MF, Ternier R, Jerome JG, Matias WR, Harris JB, Ivers LC. Long-term effectiveness of one and two doses of a killed, bivalent, whole-cell oral cholera vaccine in Haiti: an extended case-control study. Lancet Glob Health. 2018;6:e1028–e1035.
    1. Thiem VD, Deen JL, von Seidlein L, et al. Long-term effectiveness against cholera of oral killed whole-cell vaccine produced in Vietnam. Vaccine. 2006;24:4297–4303.
    1. Clemens JD, Sack DA, Harris JR, et al. Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up. Lancet. 1990;335:270–273.
    1. Qadri F, Ali M, Chowdhury F, et al. Feasibility and effectiveness of oral cholera vaccine in an urban endemic setting in Bangladesh: a cluster randomised open-label trial. Lancet. 2015;386:1362–1371.
    1. Khan IA, Saha A, Chowdhury F, et al. Coverage and cost of a large oral cholera vaccination program in a high-risk cholera endemic urban population in Dhaka, Bangladesh. Vaccine. 2013;31:6058–6064.
    1. Najnin N, Leder K, Qadri F, et al. Impact of adding hand-washing and water disinfection promotion to oral cholera vaccination on diarrhoea-associated hospitalization in Dhaka, Bangladesh: evidence from a cluster randomized control trial. Int J Epidemiol. 2017;46:2056–2066.
    1. WHO The treatment of diarrhoea: a manual for physicians and other senior health workers (4th revision)
    1. Ansaruzzaman M, Bhuiyan NA, Nair BG, et al. Cholera in Mozambique, variant of Vibrio cholerae. Emerg Infect Dis. 2004;10:2057–2059.
    1. Halloran ME, Struchiner CJ, Longini IM., Jr Study designs for evaluating different efficacy and effectiveness aspects of vaccines. Am J Epidemiol. 1997;146:789–803.
    1. Lin DY, Wei L-J, Ying Z. Checking the Cox model with cumulative sums of martingale-based residuals. Biometrika. 1993;80:557–572.
    1. Lin DY, Wei L-J. The robust inference for the Cox proportional hazards model. J Am Stat Assoc. 1989;84:1074–1078.
    1. Reid N, Cracpeau H. Influence functions for proportional hazards regression. Biometrika. 1985;72:1–9.
    1. Lee EW, Wei LJ, Amato DA, Leurgans S. In: Survival analysis: state of the art. Klein JP, Goel PK, editors. Springer; Berlin: 1992. Cox-type regression analysis for large numbers of small groups of correlated failure time observations; pp. 237–247.
    1. Clemens JD, van Loon FF, Rao M, et al. Nonparticipation as a determinant of adverse health outcomes in a field trial of oral cholera vaccines. Am J Epidemiol. 1992;135:865–874.
    1. Ali M, Qadri F, Kim DR, et al. Unmasking herd protection by an oral cholera vaccine in a cluster-randomized trial. Int J Epidemiol. 2019;48:1252–1261.
    1. Pezzoli L. Global oral cholera vaccine use, 2013–2018. Vaccine. 2020;38(suppl 1):A132–A140.
    1. Martin S, Lopez AL, Bellos A, et al. Post-licensure deployment of oral cholera vaccines: a systematic review. Bull World Health Organ. 2014;92:881–893.
    1. Taylor DL, Kahawita TM, Cairncross S, Ensink JH. The impact of water, sanitation and hygiene interventions to control cholera: a systematic review. PLoS One. 2015;10
Uncited References
    1. Clemens J, Shin S, Ali M. New approaches to the assessment of vaccine herd protection in clinical trials. Lancet Infect Dis. 2011;11:482–487.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅